Interest of Ascorbic Acid in the Management of Pneumonia in Elderly People Hospitalized.

• Status: Completed
• Trial end date: 2016-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Pneumonia is the second common infection and its risk increases for elderly. In this population, it is the first cause of mortality by infections, and source of many complications. Geriatric studies had shown the high prevalence of ascorbic acid 's deficiency, especially in older hospitalized people. It is well known that vitamin C is one of the key of the immune system, it has a scavenger's role in case of aggression like sepsis. A Cochrane database published in 2013 analyzed the impact of vitamin C for preventing and treating pneumonia. Two randomized studies showed a benefit on respiratory symptoms for patients treated by vitamin C, and for one of those studies it was noted a significant reduction of mortality. The main objective of our study is first to determine the impact on respiratory symptoms of an adjuvant treatment by vitamin C for the management of pneumonia in older people hospitalized, and then evaluate its impact on functional status.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Bordeaux
• Treatments: Ascorbic Acid; Vitamins

Criteria

Inclusion Criteria:

• people aged ≥ 75 years old

• pneumonia's symptoms according to the SPILF (Société de Pathologie Infectieuse de Langue Française) :

• cough

• at least one respiratory sign : dyspnea, chest pain, wheezing, and local signs at the auscultation

• at least one general sign suggesting an infection : fever, sweat, headache, sore joints, common cold

• pneumonia's symptoms developed between the admission's date in the unit care and the seventh day included

Exclusion Criteria:

• palliative care's patients

• patients with deglutition's disorders

• patients who can't be on a drip

• antibiotherapy since more one day

• other concomitant infection(s)

• patients who can't make their own transfer 15 days ago

• patients who have a NYHA score at IV 15 days ago

• patients with contraindication to a vitamin C treatment : hemochromatosis, oxalo-calcic lithiasis antecedent, G6PD deficit (Glucose 6 Phosphate Dehydrogenase), and treatment by Deferoxamine